Jennifer Low: I think the way to interpret that data, this is a Phase 1, all solid tumor cancer patients. The primary goal was to look at safety. We were very pleased to have some patients who did have a longer time on study, and so we wanted to communicate that. But we are really happy that this is monotherapy, this is our patients who generally do not have a lot of options, who had multiple prior lines of therapy in this group that was once a month. This was also during the dose escalation, and so many patients who are receiving sub-therapeutic doses. So it’s — I think this really sets us up well for the upcoming Phase 2a data that we hope to present that we’ve been enrolling this year. And I think it’s just — it’s really also a sort of proof that 23andMe Therapeutics, so we’ve created a really solid molecule that has with PK and has safety is consistent with the mechanism of this drug.
David Lebowitz : One last follow-up here. With respect to the candidate, is there any mechanistic rationale you can provide for what cancers you might ultimately choose to target?
Anne Wojcicki : So the nice thing about the target that we’ve chosen in CD200R1 and its ligand CD200, it is expressed in a variety of tumor types. And these tumor — that expression will probably play a role in which patients we chose to move forward with. But for the Phase 1a the disease areas that we chose to do our expansion cohorts and was primarily driven by CD200 and 200R1 expression and the likely populations we would have in the late-stage Phase 3 population. In other words, we have in therapy.
Operator: [Operator Instructions] And now I will turn it over to Ian for any further questions.
Ian Cooney: Thank you, Carmin. I will now read the top shareholder questions from our say technologies platform. This one is for Anne. What are you doing to increase the value of the company?
Anne Wojcicki : That is a great question. This is obviously a top priority for all of us within 23andMe. I just want to remind you all, we are all shareholders. I am a large shareholder. It is a top priority for us to be able to demonstrate and get the value that we think that we all should be getting from the company. So first and foremost, the consumer business is full of incredible opportunity. And that is why we — obviously, we have the health and the ancestry products. We have been pivoting into a subscription product more and more for all of our customers. Total Health, I think, is the future of where we are thinking about everything. There is absolutely an opportunity to be able to have more and more people getting access to an exome access to their blood, access to clinical care that is focused on prevention.
So I absolutely believe there’s an incredible opportunity for all of us on the consumer side. On partnerships, you can see that we already did our GSK partnership, which we announced. There is a real opportunity for 23andMe to be helping the entire therapeutics and research business, world about how they can recruit better, how they can eventually promote, how can they can leverage genetics to their drug discovery and be more efficient and more likely to be successful because of the utilization of genetics. So by being at the end of the GSK collaboration, we really have a significant opportunity now for doing those types of collaborations. So last, I am thrilled about our therapeutics team and our opportunities that we have here, the IO program that Jennifer just stated, I think our goal potential, the SITC data, I think, shows that.
We have our P014 asset which is slated to file IND short — as we said shortly, as well as we have the opportunities for all of our discovery that will be wholly owned now by 23andMe. So we have previously said that will be focused on inflammation and immunology. We have a team that has been working for years with GSK on moving from data to the end process of actually having programs in the clinics with humans filing the INDs ourselves, actually going from, again, the very beginning all the way actually into humans. And I think that there’s a huge opportunity for us there. And then lastly, I just want to conclude with the fact that genetics, I think is a critical part that needs to be part of everyone’s like their health care, how they are actually making decisions in their health as well as part of the therapeutic process.
And we have — we just want to reiterate the fact that if you start with human genetic information, you are more than twice as likely to be successful with your discovery. So again, genetics should become an integral part of our life, whether it’s in our personal life and our health or in our therapeutics life, and how we are taking medications and developing medication.
Ian Cooney: Thank you, Anne. Next question is for Joe. What is the company’s plan to address liquidity and decreased cash burn?
Joseph Selsavage: Thank you, Ian. I mean, first and foremost, the company is trying to increase its revenue. And basically, as Anne mentioned, really focus on the growth of margin. For us, that means less promotions, and we increased prices of our kits and subscriptions, which has been well received by consumers. And really, we’ve seen better-than-expected results there. We’ve also launched new products. Basically, we talked a little bit of health, now paying Total Health, which we launched yesterday. And then we actually announced the GSK deal, which also provided $20 million in additional cash for the company. And our corporate development team is continually working on additional potential deals as well. And then on the cost structure, we’ve taken significant efforts in this fiscal year to reduce our cost structure.
First, we announced previously, we’ve done reductions in force to rebalance our employee headcount. Next is we are also working with our therapeutics team and making sure we’re utilizing our capital on the assets that really will drive the most shareholder value there. And help us also reduce our cash and cash burn. I mean, all of these efforts will help us decrease our cash burn and extend our current cash runway. So we’re pleased with the efforts to date.
Ian Cooney: Thanks, Joe. This one is for Jennifer. Can you explain the historical lack of transparency around your drug development efforts? And do you plan to be more transparent moving forward?
Jennifer Low: Thank you. We have been and continue to be somewhat constrained in what we can talk about with our GSK collaboration programs, and largely, those we do not talk about. However, we are — as you can see, we’ve been publishing quite a bit on 610. We will, like many other companies, continue to announce scientifically relevant data out scientific conferences, and we do have a lot of information that we’re planning on just those things just like we did at SITC last week. We’re also excited to be talking more about our new program with [014] program. It’s an NK cell activator, and you’re going to hear more from us about that mechanism and our plans moving forward. And finally, we’re updating our therapeutics website to be launched within the next few months, and that will also provide more information than we have in the past.
